A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
The line-up is revealed to include Merck & Co and J&J itself.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
A phase 1 study of OKI-219 reads out imminently.
Bristol will test the bispecific in two new lung indications.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
After Genmab’s exit two more ADCs enter human trials.
